By clicking "Accept", you agree to the storing of cookies on your device to analyze site usage. Privacy Policy
Accept
Lighting the Way
Toward Antitumor Immunity
Lighting the Way
Toward Antitumor Immunity

Istari’s Lerapolturev (formerly PVSRIPO)—Elevating the Standard of Cancer Care With a Multifaceted Approach to Ignite a Systemic Anticancer Response

Lerapolturev Lighting the Way

Immune checkpoint inhibitors have revolutionized cancer therapy, but their success is limited by a lack of preexisting anticancer T cells or the inability of anticancer T cells to overcome the immunosuppressive tumor microenvironment.

Various approaches to overcoming these challenges have been investigated, but the complexity of the immune system suggests that intervention at multiple points is required to effectively activate antitumor immunity.

Lerapolturev—a Unique Immune Activator With Multiple Mechanisms to Stimulate a Powerful Anticancer Response

The ONLY immune activator based on the poliovirus
Because it is based on the live attenuated Sabin type 1 oral polio vaccine and polio vaccination is nearly universal, lerapolturev leverages the powerful memory response against polio to amplify the anticancer immune response.
The ONLY immune activator to target solid tumors via CD155
Because CD155, the poliovirus receptor, is present on virtually all solid tumor types, lerapolturev offers remarkable potential across a wide range of solid tumors. Lerapolturev exhibits direct antitumor cytotoxic effects.
The ONLY immune activator to engage APCs in promoting an interferon-driven anticancer T cell response
Lerapolturev also targets key antigen presenting cells (APCs) within the tumor microenvironment, where it stimulates the robust type-I/III interferon-dominant response required for anticancer T cell activation.

Find out more about lerapolturev's mechanism of action by watching this video.

The LUMINOS Clinical Trial Program Is Rapidly Expanding

Lerapolturev has been administered to more than 200 patients and is currently the subject of multiple ongoing phase 2 trials across 6 potential solid tumor indications.

Trial
Tumor Type
Preclinical
Phase 1
Phase 2
Phase 3
NCT02986178
rGBM
Lerapolturev Monotherapy
LUMINOS-101
rGBM
Lerapolturev + pembrolizumab
LUMINOS-102
Melanoma
Lerapolturev + anti–PD-1/L1
LUMINOS-103
Muscle-invasive bladder cancer (MIBC)
Head and neck squamous cell cancer (HNSCC)
Lerapolturev + anti–PD-1/L1*
Lerapolturev + anti–PD-1/L1*
Istari clinical trial pipeline
See our clinical trials

*Patients will be treated with lerapolturev monotherapy during phase 1 and lerapolturev in combination with anti–PD-1/L1 during phase 2.

Strong Support From FDA

Strong Support
From FDA

Glioblastoma

Recurrent GBM

Breakthrough Therapy
Orphan Drug Designation

Melanoma

Refractory melanoma

Fast Track
Orphan Drug Designation

Lerapolturev has been designated an Orphan Drug and granted Breakthrough Therapy Designation for recurrent glioblastoma (rGBM) by the FDA.

Lerapolturev has also been designated an Orphan Drug in advanced melanoma (Stages IIb-IV) and granted Fast Track status for patients with advanced melanoma who have disease progression after anti–PD-1/L1 therapy.

Recent News Releases

Recent News Releases

View all news